ArticleResearch and practice in thrombosis and haemostasis2025
Individualizing dosing frequency may improve the efficacy of prophylaxis in patients with von Willebrand disease-a WIL-31 subanalysis.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04052698 (Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With Von Willebrand Disease), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With Von Willebrand Disease (VWD)
Who cites it
1 citing paper in PubMed.
- Factor VIII and von Willebrand factor activity levels during long-term prophylaxis with wilate-Analyses from the WIL-31 study.Research and practice in thrombosis and haemostasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The efficacy and safety of prophylaxis with wilate, a plasma-derived von Willebrand factor/factor VIII concentrate, was demonstrated in patients with von Willebrand disease of all types in the WIL-31 study. Objectives: To investigate the reasons for and the impact of changing the dosing frequency during WIL-31. Methods: Patients received 20 to 40 IU/kg wilate 2 or 3 times weekly for 12 months. Bleeding rates were analyzed in patients who changed dosing regimen during the study. Results: Of 33 patients in WIL-31, 30 (91%) initiated prophylaxis 2 times weekly. Of these, 7 (21%) patients increased to 3 times weekly dosing during the study. Four (57%) had underlying circumstances leading to the regimen change: undiagnosed gingivitis, multiple comorbidities, severe menarche, and ongoing left/right ankle arthropathy. The median total annualized bleeding rate in these 7 patients improved from 60.6 during on-demand treatment to 24.0 on 2 times weekly (60.4% reduction) and 3.8 on 3 times weekly prophylaxis (overall reduction, 93.7%). The median spontaneous annualized bleeding rate improved from 32.2 during on-demand treatment to 5.8 on 2 times weekly (82.0% reduction) and 2.4 on 3 times weekly prophylaxis (overall reduction, 92.5%). Despite increased dosing, no von Willebrand factor or FVIII accumulation or thrombotic events were observed. Conclusion: In the WIL-31 study, a small proportion of patients increased the frequency of prophylaxis, which resulted in effective prevention of bleeding. In most cases, there were underlying medical conditions that necessitated the increased dosing frequency, indicating that personalization of prophylaxis may be beneficial in patients with von Willebrand disease. Trial registration details: NCT04052698; https://clinicaltrials.gov/study/NCT04052698.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.